Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.
- Read more about Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/moderna-announces-teencove-study-of-its-covid-19-vaccine-in-adolescents
No comments:
Post a Comment